Prendiville J, O'Brien M
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey.
Br J Hosp Med. 1997;57(8):405-9.
There is widespread consensus that a plateau has been reached in the effectiveness of known DNA interactive drugs against most malignancies. Combination treatments, dose intensification and schedule alterations (e.g. infusional and neoadjuvant treatments) represent exciting research opportunities and possibly the means for making meaningful progress. However, frustration with the slow pace of even these most novel approaches has led to a search for newer drug targets and great expectations of new drugs.
人们普遍认为，已知的DNA相互作用药物对大多数恶性肿瘤的疗效已达到瓶颈。联合治疗、剂量强化和给药方案改变（如输注和新辅助治疗）是令人兴奋的研究方向，可能是取得实质性进展的途径。然而，即使是这些最新颖的方法，其进展缓慢也令人沮丧，这促使人们寻找新的药物靶点，并对新药寄予厚望。
